Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon Safety Study in Blind Individuals with N24HSWD
NCT01218789Phase 3Active, not recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Oct 2010
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 3, open-label trial of tasimelteon in Non-24-hour sleep-wake disorder (N24SWD), sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Safety Evaluations at 52 weeks. Started Oct 2010; status: active, not recruiting.
02
Drugs
tasimelteon
03
Conditions
Non-24-hour sleep-wake disorder (N24SWD)
Beyond the preview
Go deeper on NCT01218789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218789.